← Summit Therapeutics (SMMT)

Summit Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

  • 4Nov. 20, 2026, 6:22 p.m. ETView on SEC.gov
  • 4Nov. 20, 2026, 6:26 p.m. ETView on SEC.gov
  • 8-KNov. 18, 2026, 8:16 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

    AI summary, unreviewedSummit Therapeutics Announces Planned Phase III HARMONi-10 Trial of Ivonescimab vs Durvalumab in Stage III NSCLC

  • 8-KNov. 16, 2026, 6:08 a.m. ETView on SEC.govOur explainer

    Other events · Financial statements and exhibits

    AI summary, unreviewedSummit Therapeutics Receives FDA Complete Response Letter for Ivonescimab BLA in Second-Line EGFR-Mutated NSCLC, Citing Lack of Statistically Significant Overall Survival Benefit

  • 4Nov. 16, 2026, 7:49 p.m. ETView on SEC.gov
  • 4Nov. 16, 2026, 8:23 p.m. ETView on SEC.gov
  • 4Nov. 16, 2026, 8:26 p.m. ETView on SEC.gov
  • 10-QNov. 4, 2026, 5:08 p.m. ETView on SEC.gov
  • 8-KNov. 4, 2026, 4:51 p.m. ETView on SEC.gov

    Results of operations and financial condition · Amendments to articles or bylaws; fiscal year change · Submission of matters to a vote of security holders · Financial statements and exhibits

    AI summary, unreviewedSummit Therapeutics Q3 2026 non-GAAP net loss of $0.20 per share, in line with consensus; GAAP loss $0.26 per share, narrower than $0.31 a year earlier

  • 8-KNov. 4, 2026, 5:22 p.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

    AI summary, unreviewedSummit Therapeutics files legal opinion (Exhibit 5.1) tied to prospectus supplement under its S-3 shelf registration

  • 4Oct. 14, 2026, 4:07 p.m. ETView on SEC.gov
  • 8-KSept. 28, 2026, 9:39 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Unregistered sales of equity securities · Amendments to articles or bylaws; fiscal year change · Other events · Financial statements and exhibits

  • 8-KSept. 15, 2026, 8:44 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

  • 8-KSept. 14, 2026, 8:37 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

  • 8-KSept. 3, 2026, 9:21 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

  • 8-KAug. 26, 2026, 9:17 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

  • 8-KAug. 5, 2026, 7:32 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits